| Title |
Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α5β1 integrin monoclonal antibody (volociximab) in cancer patients
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, May 2009
|
| DOI | 10.1007/s00280-009-1023-8 |
| Pubmed ID | |
| Authors |
Chee M. Ng, S. Bai, C. H. Takimoto, M. T. Tang, A. W. Tolcher |
| Abstract |
Volociximab is a chimeric IgG(4) that is being developed as a novel first-in-class anti-angiogenic, α(5)β(1) integrin inhibitor for the treatment of solid tumors. A mechanism-based pharmacokinetic (PK)/pharmacodynamic (PD) model was developed to investigate the dynamic interaction between volociximab concentrations and free monocyte α(5)β(1) integrin levels in cancer patients. |
Mendeley readers
The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 3% |
| Belgium | 1 | 3% |
| Unknown | 30 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 15 | 47% |
| Student > Ph. D. Student | 7 | 22% |
| Student > Bachelor | 2 | 6% |
| Other | 1 | 3% |
| Student > Master | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 5 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 19% |
| Medicine and Dentistry | 6 | 19% |
| Agricultural and Biological Sciences | 6 | 19% |
| Chemistry | 3 | 9% |
| Biochemistry, Genetics and Molecular Biology | 1 | 3% |
| Other | 5 | 16% |
| Unknown | 5 | 16% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 January 2024.
All research outputs
#7,856,604
of 23,815,455 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#688
of 2,501 outputs
Outputs of similar age
#38,734
of 112,677 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#3
of 14 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,501 research outputs from this source. They receive a mean Attention Score of 4.1. This one is in the 32nd percentile – i.e., 32% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 112,677 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 18th percentile – i.e., 18% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one is in the 7th percentile – i.e., 7% of its contemporaries scored the same or lower than it.